과제정보
연구 과제 주관 기관 : Korea Science and Engineering Foundation, Chonnam National University
참고문헌
- Boyle, W.J., Simonet, W.S., and Lacey, D.L. (2003). Osteoclast differentiation and activation. Nature 423, 337-342 https://doi.org/10.1038/nature01658
- Hahn, G., Lehmann, H.D., Kurten, M., Uebel, H., and Vogel, G. (1968). [On the pharmacology and toxicology of silymarin, an antihepatotoxic active principle from Silybum marianum (L.) Gaertn]. Arzneimittel-Forschung 18, 698-704
- Hsu, H., Lacey, D.L., Dunstan, C.R., Solovyev, I., Colombero, A., Timms, E., Tan, H.L., Elliott, G., Kelley, M.J., Sarosi, I.I et al. (1999). Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96, 3540-3545 https://doi.org/10.1073/pnas.96.7.3540
- Kim, N., Takami, M., Rho, J., Josien, R., and Choi, Y. (2002). A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J. Exp. Med. 195, 201-209 https://doi.org/10.1084/jem.20011681
- Kim, K., Kim, J.H., Lee, J., Jin, H.M., Lee, S.H., Fisher, D.E., Kook, H., Kim, K.K., Choi, Y., and Kim, N. (2005a). Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activationinduced cytokine-mediated osteoclastogenesis. J. Biol. Chem. 280, 35209-35216 https://doi.org/10.1074/jbc.M505815200
- Kim, N., Kadono, Y., Takami, M., Lee, J., Lee, S.H., Okada, F., Kim, J.H., Kobayashi, T., Odgren, P.R., Nakano, H., et al. (2005b). Osteoclast differentiation independent of the TRANCE-RANKTRAF6 axis. J. Exp. Med. 202, 589-595 https://doi.org/10.1084/jem.20050978
- Kim, K., Kim, J.H., Lee, J., Jin, H.M., Kook, H., Kim, K.K., Lee, S.Y., and Kim, N. (2007). MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 109, 3253-3259 https://doi.org/10.1182/blood-2006-09-048249
- Kim, K., Lee, S.H., Ha Kim, J., Choi, Y., and Kim, N. (2008). NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DCSTAMP). Mol. Endocrinol. (Baltimore, Md.) 22, 176-185 https://doi.org/10.1210/me.2007-0237
- Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., et al. (2000). Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/ RANKL-RANK interaction. J. Exp. Med. 191, 275-286 https://doi.org/10.1084/jem.191.2.275
- Koga, T., Inui, M., Inoue, K., Kim, S., Suematsu, A., Kobayashi, E., Iwata, T., Ohnishi, H., Matozaki, T., Kodama, T., et al. (2004). Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428, 758-763 https://doi.org/10.1038/nature02444
- Kwak, H.B., Sun, H.M., Ha, H., Lee, J.H., Kim, H.N., and Lee, Z.H. (2008). AG490, a Jak2-specific inhibitor, induces osteoclast survival by activating the Akt and ERK signaling pathways. Mol. Cells 26, 436-442
- Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 https://doi.org/10.1016/S0092-8674(00)81569-X
- Lee, Z.H., and Kim, H.H. (2003). Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Comm. 305, 211-214 https://doi.org/10.1016/S0006-291X(03)00695-8
- Lee, S.E., Chung, W.J., Kwak, H.B., Chung, C.H., Kwack, K.B., Lee, Z.H., and Kim, H.H. (2001). Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J. Biol. Chem. 276, 49343-49349 https://doi.org/10.1074/jbc.M103642200
- Lee, J., Kim, K., Kim, J.H., Jin, H.M., Choi, H.K., Lee, S.H., Kook, H., Kim, K.K., Yokota, Y., Lee, S.Y., et al. (2006). Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood 107, 2686-2693 https://doi.org/10.1182/blood-2005-07-2798
- Li, L.H., Wu, L.J., Tashiro, S.I., Onodera, S., Uchiumi, F., and Ikejima, T. (2006). The roles of Akt and MAPK family members in silymarin's protection against UV-induced A375-S2 cell apoptosis. Int. Immunopharmacol. 6, 190-197 https://doi.org/10.1016/j.intimp.2005.08.003
- Manna, S.K., Mukhopadhyay, A., Van, N.T., and Aggarwal, B.B. (1999). Silymarin suppresses TNF-induced activation of NFkappa B, c-Jun N-terminal kinase, and apoptosis. J. Immunol. 163, 6800-6809
- Ramasamy, K., and Agarwal, R. (2008). Multitargeted therapy of cancer by silymarin. Cancer Lett. 269, 352-362 https://doi.org/10.1016/j.canlet.2008.03.053
- Rho, J., Takami, M., and Choi, Y. (2004). Osteoimmunology: interactions of the immune and skeletal systems. Mol. Cells 17, 1-9
- Singh, R.P., and Agarwal, R. (2002). Flavonoid antioxidant silymarin and skin cancer. Antioxid. Redox Signal. 4, 655-663 https://doi.org/10.1089/15230860260220166
- Singh, R.P., and Agarwal, R. (2005). Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur. J. Cancer 41, 1969-1979 https://doi.org/10.1016/j.ejca.2005.03.033
- Singh, R.P., Dhanalakshmi, S., Tyagi, A.K., Chan, D.C., Agarwal, C., and Agarwal, R. (2002). Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res. 62, 3063-3069
- Singh, R.P., Dhanalakshmi, S., Agarwal, C., and Agarwal, R. (2005). Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 24, 1188-1202 https://doi.org/10.1038/sj.onc.1208276
- Suda, T., Jimi, E., Nakamura, I., and Takahashi, N. (1997). Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function. Methods Enzymol. 282, 223-235 https://doi.org/10.1016/S0076-6879(97)82110-6
- Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T., and Martin, T.J. (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357 https://doi.org/10.1210/er.20.3.345
- Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J., et al. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901 https://doi.org/10.1016/S1534-5807(02)00369-6
- Walsh, M.C., Kim, N., Kadono, Y., Rho, J., Lee, S.Y., Lorenzo, J., and Choi, Y. (2006). Osteoimmunology: interplay between the immune system and bone metabolism. Ann. Rev. Immunol. 24, 33-63 https://doi.org/10.1146/annurev.immunol.24.021605.090646
- Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597-3602 https://doi.org/10.1073/pnas.95.7.3597
피인용 문헌
- Pim-1 Regulates RANKL-Induced Osteoclastogenesis via NF-κB Activation and NFATc1 Induction vol.185, pp.12, 2009, https://doi.org/10.4049/jimmunol.1000885
- The Role of Osteoclast-Associated Receptor in Osteoimmunology vol.186, pp.1, 2011, https://doi.org/10.4049/jimmunol.1002483
- 몇 가지 주요 식용버섯의 생리기능성 물질 탐색과 파골세포 분화 저해물질의 생산 vol.40, pp.2, 2009, https://doi.org/10.4489/kjm.2012.40.2.114
- SLAT negatively regulates RANKL-induced osteoclast differentiation vol.36, pp.3, 2009, https://doi.org/10.1007/s10059-013-0159-x
- Mediators of Inflammation-Induced Bone Damage in Arthritis and Their Control by Herbal Products vol.2013, pp.None, 2009, https://doi.org/10.1155/2013/518094
- Silibinin Inhibits LPS-Induced Macrophage Activation by Blocking p38 MAPK in RAW 264.7 Cells vol.21, pp.4, 2009, https://doi.org/10.4062/biomolther.2013.044
- Acteoside Suppresses RANKL-Mediated Osteoclastogenesis by Inhibiting c-Fos Induction and NF-κB Pathway and Attenuating ROS Production vol.8, pp.12, 2013, https://doi.org/10.1371/journal.pone.0080873
-
Silymarin Inhibits Morphological Changes in LPS-Stimulated Macrophages by Blocking NF-
${\kappa}B$ Pathway vol.19, pp.3, 2009, https://doi.org/10.4196/kjpp.2015.19.3.211 - Molecular signaling mechanisms behind polyphenol-induced bone anabolism vol.16, pp.6, 2009, https://doi.org/10.1007/s11101-017-9529-x
- The Incorporation of Strontium to Improve Bone-Regeneration Ability of Mesoporous Bioactive Glasses vol.11, pp.5, 2018, https://doi.org/10.3390/ma11050678
- Dietary nutraceuticals as backbone for bone health vol.36, pp.6, 2018, https://doi.org/10.1016/j.biotechadv.2018.03.014
- Modulatory effects of silibinin in cell behavior during osteogenic phenotype vol.120, pp.8, 2009, https://doi.org/10.1002/jcb.28616
- Local administration with silymarin could increase osseointegration of hydroxyapatite-coated titanium implants in ovariectomized rats vol.34, pp.5, 2009, https://doi.org/10.1177/0885328219863290
- Potential Advantages of Bioactive Compounds Extracted From Traditional Chinese Medicine to Inhibit Bone Destructions in Rheumatoid Arthritis vol.11, pp.None, 2009, https://doi.org/10.3389/fphar.2020.561962
- Emerging Natural-Product-Based Treatments for the Management of Osteoarthritis vol.10, pp.2, 2009, https://doi.org/10.3390/antiox10020265